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Abstract
Background: Ischemia-reperfusion (I/R) injury contributes to organ dysfunction in a variety of clinical disorders, including
myocardial infarction, stroke, organ transplantation, and hemorrhagic shock. Recent investigations have demonstrated that
apoptosis as an important mechanism of cell death leading to organ dysfunction following I/R. Intracellular danger-
associated molecular patterns (DAMPs) released during cell death can activate cytoprotective responses by engaging
receptors of the innate immune system.
Methodology/Principal Findings: Ischemia was induced in the mouse hind limb by tourniquet or in the heart by coronary
artery ligation. Reperfusion injury of skeletal or cardiac muscle was markedly reduced by intraperitoneal or subcutaneous
injection of recombinant human (rh)BCL2 protein or rhBCL2-related protein A1 (BCL2A1) (50 ng/g) given prior to ischemia
or at the time of reperfusion. The cytoprotective activity of extracellular rhBCL2 or rhBCL2A1 protein was mapped to the
BH4 domain, as treatment with a mutant BCL2 protein lacking the BH4 domain was not protective, whereas peptides
derived from the BH4 domain of BCL2 or the BH4-like domain of BCL2A1 were. Protection by extracellular rhBCL2 or
rhBCL2A1 was associated with a reduction in apoptosis in skeletal and cardiac muscle following I/R, concomitant with
increased expression of endogenous mouse BCL2 (mBCL2) protein. Notably, treatment with rhBCL2A1 protein did not
protect mice deficient in toll-like receptor-2 (TLR2) or the adaptor protein, myeloid differentiation factor-88 (MyD88).
Conclusions/Significance: Treatment with cytokine-like doses of rhBCL2 or rhBCL2A1 protein or BH4-domain peptides
reduces apoptosis and tissue injury following I/R by a TLR2-MyD88-dependent mechanism. These findings establish a novel
extracellular cytoprotective activity of BCL2 BH4-domain proteins as potent cytoprotective DAMPs.
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Introduction
Cellular injury resulting from tissue damage induced by a
variety of insults elicits host defense and repair responses. With
primary necrosis or secondary necrosis (when apoptotic cells are
not cleared by phagocytosis) intracellular constituents, nuclear as
well as cytoplasmic, are released extracellularly. In the extracel-
lular environment these intracellular constituents may act as
danger-associated molecular patterns (DAMPs) or ‘alarmins’,
engaging receptors on immune or adjacent cells and triggering
activation of the innate immune system (reviewed in [1–3]).
Under some circumstances, pro-inflammatory responses to
intracellular DAMPs may exacerbate tissue injury, whereas
under other conditions DAMPs may elicit cytoprotective
responses.
The BCL2 family consists of anti- and pro-apoptotic proteins
that have been extensively studied as intracellular regulators of cell
death (reviewed in [4]). In previous studies in a murine model of
sepsis induced by cecal ligation and puncture (CLP), we found that
intraperitoneal (ip) instillation of myeloid cells over-expressing
BCL2 protected normal mice against death following CLP [5].
Since the adoptively transferred cells eventually undergo necrosis
or apoptosis with secondary necrosis, we examined the possibility
that BCL2 protein itself was the transferred protective factor.
Indeed, we found that administration of BCL2 protein alone was
sufficient to reduce sepsis-induced lethality (manuscript in
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novel extracellular cytoprotective function against severe I/R
injury for two anti-apoptotic members of the BCL2 family, BCL2
and BCL2-related protein A1 (BCL2A1), which have previously
been thought to function only intracellularly. We show that
exogenously administered recombinant human BCL2 (rhBCL2) or
rhBCL2A1 protein and synthetic peptides derived from the BH4
domain of BCL2 or the BH4-like domain of BCL2A1 [6] confer
protection against I/R injury of hind limb skeletal muscle or
cardiac muscle. This protection was associated with increased
expression of endogenous mouse BCL2 protein and reduced
apoptosis in the muscle subjected to I/R injury. The protection
afforded by rhBCL2A1 protein was not seen in mice deficient in
either toll-like receptor-2 (TLR2) or the adaptor molecule MyD88,
indicating that the protective pathway required TLR2-MyD88
signaling. We propose that BCL2, BCL2A1, and BH4-domain
peptides are cytoprotective DAMPs.
Materials and Methods
Animals
All protocols were approved by the Animal Care and Use
Committee of the University of Washington and complied with the
NIH guidelines for care and use of animals. Mice were maintained
at the University of Washington, Department of Comparative
Medicine facility. Sprague-Dawley rats and C57BL/6 mice were
obtained from Charles River Breeding Laboratory (Wilmington,
MA). C3H/HeJ mice were obtained from Jackson Laboratory
(Bar Harbor, ME). TLR2
2/2 and MyD88
2/2 mice were bred in
the animal facility at the University of Washington and breeding
pairs were a gift of Dr. S. Akira (Osaka, Japan).
Proteins and Peptides
rhBCL2, rhUbiquitin, rhBIM (BCL2-like 11; BCL2L11), and
rhBCL2A1 were purchased from R&D Systems (Minneapolis,
MN). Mutant rhBCL2 (-BH4) and rhBAX (BCL2-associated X)
were purchased from ProteinX (San Diego, CA). rhBCL2 protein
consisted of amino acids 1–212 (accession number P10415) of
human Bcl-2, thus the carboxyl terminal was deleted and replaced
with a ten histidine tag. rhBCL2A1 (BCL2-related protein A1)
protein consisted of amino acids 1–152 of human BCL2-related
protein BCL2A1 (accession number NP004040) missing the
carboxyl terminal hydrophobic domain that was replaced with a
six histidine tag. rhUbiquitn consisted of amino acids 1–76
(accession number CAA28495.1) containing the amino acids
ATVID followed by a 10 histidine tag at its amino terminal. rhBim
consisted of amino acids 2–120 (accession number AAC39594) of
human Bim long, with a deleted carboxyl terminal transmem-
brane domain replaced with a six histidine tag. Purity of the
proteins was .95% for the recombinant proteins as determined by
SDS-PAGE and visualized by silver stain per manufacturer (R&D
Systems). Endotoxin concentration in the recombinant protein was
less than 0.15 EU/mg protein (R&D Systems).
BCL2-BH4 peptide consisted of amino acid 7–31 (TGYDN-
REIVMKYIHYKLSQRGYEWD-CONH2 (SynPep, Dublin, CA)).
BCL2A1-BH4 peptide consisted of amino acids 6–30 (FGYIYRLAQ-
DYLQCVLQIPQPGSGP-CONH2 (SynPep)). BAK-BH3 peptide
consisted of amino acids 72–87 (GQVGRQLAIIGDDIN; R&D
Systems). Scrambled peptide had the sequence TWHMYGNQR-
DYIGDRSKIVYKLEYE-CONH2 (SynPep).
Hind Limb I/R
In a previous study, we investigated anti-adhesion therapy in I/
R injury of mouse hind limb skeletal muscle. We found that anti-
adhesion therapy afforded significant protection against brief
ischemia (30–60 minutes) followed by reperfusion [7]. Surprising-
ly, only a modest extension of ischemic time to 90 minutes
produced a marked increase in muscle injury following reperfu-
sion. Importantly, anti-adhesion therapy failed to protect against
I/R injury with 90 minutes of ischemia, whereas anti-apoptotic
therapy with a broad-spectrum caspase inhibitor was protective.
These results indicated that tissue injury with prolonged ischemia
was due to apoptosis rather than to leukocyte-mediated inflam-
mation [7]. We proposed that brief ischemia was not an accurate
model of human disease, and therefore we have used only
prolonged ischemia in the current studies of hind limb I/R.
I/R of hind limbs was accomplished by cross-clamping of the
aorta [7] in mice or by tourniquet [8] in mice and rats. Briefly, in
the aorta cross-clamp experiments mice were pretreated with
buprenorphine, anesthetized with halothane or isoflurane, a
midline abdominal incision made, and the vena cava and aorta
carefully separated. A small micro-vascular clamp was applied to
the aorta distal to the renal arteries. The peritoneum and skin were
then closed. For hind limb I/R induced by tourniquets in mice,
bilateral tourniquets (Latex O-rings) were applied above the
greater trochanter using the McGivney Hemorrhoid Ligator
(Miltex, York, PA). Mice were maintained in a supine position
under halothane or isoflurane in an incubator at 30uC during the
90-minute ischemic period. For hind limb I/R in rats, a #31
Sparco rubber band was placed as high on the thigh as possible on
both legs and turned 7 times. The rats were maintained on
isoflurane during the 90-minute period of ischemia.
The aortic clamp or the hind limb tourniquet was removed at the
end of ischemia to establish reperfusion. With aorta clamping, the
peritoneum and skin were closed, and mice were allowed to recover
in the 30uC incubator in order to maintain normal body
temperature. For both aorta clamping and tourniquet I/R,
reperfusion was continued for 3 hours. The animals were then
killed by exsanguination under ketamine anesthesia, and blood
samples were taken for plasma creatine kinase (CK) determination
by an automated analyzer. Muscle samples were taken from the left
leg, fixed in 4% formalin, and processed for histological evaluation,
including terminal deoxynucleotidyl transferase–mediated dUTP
nick end-labeling (TUNEL) assay and immunocytochemistry (ICC).
In some experiments, reperfusion was continued for 24 hours
and injury was assessed by mitochondrial function rather than CK
release. Anesthetized mice were subjected to 90 minutes of
tourniquet ischemia as described above followed by overnight
reperfusion. Mice were treated by a subcutaneous injection of 1 mg
of either rhBCL2A1 or rhBim at the time of reperfusion or after
4 hours of reperfusion. The following day, mice were killed, the
previously ischemic muscle removed, and tissue viability measured
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT)
[9]. Briefly, the excised muscle tissue was cut into pieces to increase
the surface area and uptake of MTT. The tissue sections were
placed in 3 ml of PBS supplemented with 60 ml of 5 mg/ml MTT
and incubated for 3 hours at 37uC on a shaker. Samples were
removed, blotted dry and the formazan salt extracted in 3 ml of 2-
propanol overnight at 37uC in the dark. Absorbance at 570 nm of
200 ml of the solution was determined and normalized to the dry
weight of the tissue. Viable mitochondria reduce MTT to a water-
insoluble salt that is soluble in isopropanol and can be extracted by
isopropanol. Live tissue with functional mitochondria will therefore
have an increased optical density relative to dead tissue.
Cardiac I/R
Two protocols were used for myocardial I/R. In protocol A,
mice were treated with either rhBCL2 (1 mg/mouse) or rhBim
Extracellular BCL2 proteins
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The ischemic period was 60 minutes, followed by 2 hours of
reperfusion. In protocol B, mice were treated with rhBCL2A1
(1 mg/mouse) or with rhBim (1 mg/mouse) given at the time of
reperfusion, followed by 24 hours of reperfusion.
On the day of experiment, mice were pretreated with
buprenorphine, anesthetized with isoflurane, their tracheae
intubated, and placed on mechanical ventilation. A left thoracot-
omy was performed, the left anterior descending (LAD) artery
located, and a ligature placed approximately 2–3 mm from the tip
of the left auricle. A small piece of polyethylene tubing (PE-10) was
used to secure the ligature taking care to prevent damage to the
artery. Coronary occlusion and reperfusion were confirmed by
visual inspection under a dissecting microscope by observing color
changes of the tissue. Following the period of reperfusion specified
by the protocol, mice were killed by exsanguination under
anesthesia. The LAD was again ligated at original location and
the aorta occluded. The infarct size was evaluated by double
staining using 1.5% Evans blue dye (Sigma) and 1% triphenylte-
trazolium chloride (TTC, Sigma). The area at risk was defined as
the ratio of the area of the ischemic region to the left ventricular
area, and the infarct size was defined as the ratio of the area of the
infarct region to that of the ischemic region.
In separate experiments, mice pretreated with either rhBCL2 or
rhBim were subjected to myocardial I/R. At the end of the
reperfusion period, the heart was removed, fixed in formalin, and
tissue sections cut and stained for TUNEL or mBCL2 protein.
TUNEL and Immunocytochemistry (ICC)
Paraffin-embedded sections from leg muscle were examined for
DNA strand breaks using the TUNEL technique (In Situ Cell
Death Kit, Roche Molecular Biochemicals) as described by the
manufacturer. Labeled endothelial, skeletal muscle, or smooth
muscle cells were examined.
Skeletal or cardiac muscle was fixed in 4% formalin, paraffin
embedded, and tissue sections cut. Tissue sections (5 mm) were
subjected to antigen retrieval by boiling in citrate buffer (pH 6.0) in a
microwave oven. Tissue was stained with a rabbit anti-mouse specific
BCL2 polyclonal antibody (Upstate, Waltham, MA) or with active
caspase-3 polyclonal antibody (Cell Signaling Technology, Danvers,
MA). Immunoreactivity was detected with VECSTATIN ABC Elite
kit (Vector Labs, Burlingame, CA) with DAB (Vector Labs) as a
chromagenic substrate with hematoxylin counter-staining.
Images were acquired using a Nikon Labphot microscope with
Nikon Plan Fluor 20 Ph3DL (numerical aperture: 0.75) objective
(Nikon Instruments, Inc, NY) and Spot v.3.5.9 (Diagnostic
Instruments Sterling Heights, MI) digital imaging system. The
images from the tissue stained for mBCL2 were opened in
Photoshop (Adobe Systems Inc. San Jose, CA), and staining
intensity was determined by luminosity of the image with no
alteration to the original image.
Statistical Analysis
Results are presented as the means 6 SE of the mean. Statistical
analysis was performed by two-tailed t-test or Mann-Whitney test
using GraphPad Prism 4 software. Differences associated with
probability values of p,0.05 were considered statistically significant.
Results
Pretreatment with rhBCL2 Protein Reduces I/R Injury of
Hind Limb Skeletal and Cardiac Muscle
C57BL/6 mice were given ip injections of rhBCL2 protein
(1 mg/mouse or ,50 ng/g) or equimole amounts of rhUbiquitin
protein or rhBim, a pro-apoptotic BCL2 family protein, or the
vehicle solution on the day prior to I/R. Ischemia was produced
by cross clamping of the aorta for 90 minutes. Plasma CK was
measured as an indicator of skeletal muscle injury following
3 hours of reperfusion [10]. There was no difference in the plasma
CK concentration between the rhUbiquitin-pretreated and vehicle
control-pretreated mice following I/R, and these data were
combined. In additional experiments, there was no difference
between pretreatment with rhUbiquitin and two pro-apoptotic
members of the BCL2 family, rhBim and rhBax (data not shown).
Pretreatment with rhBCL2 resulted in significantly lower plasma
CK concentration compared with the combined control treatment
(Figure 1A).
In separate experiments, mice were subjected to 60 minutes of
LAD coronary artery occlusion followed by 2 hours of reperfusion,
and then evaluated for infarct size. C57BL/6 mice were given
rhBCL2 or rhBim by ip injection on the day prior to I/R. There
was no difference in volume of area at risk (VAAR) relative to left
ventricular volume (VLV) between the groups (Figure 1B). The
volume of infarct (Vinfarct) relative to the VLV in rhBCL2-
pretreated mice was significantly less than in rhBim-treated mice
(Figure 1B). Mean infarct size, expressed as a percent of the VAAR,
was significantly less in the rhBCL2-pretreated mice compared
with rhBim-pretreated mice (Figure 1B).
The marked reduction in I/R injury of skeletal muscle or
cardiac muscle observed following pretreatment with rhBCL2 (as
shown in Figure 1A and 1B) was associated with decreased
apoptosis as detected by TUNEL staining (Figure 1C–D).
The BCL2 Homologue rhBCL2A1 Also Reduces I/R Injury
in Hind Limb Skeletal Muscle of Mice and Rats
In order to determine whether the protection against I/R injury
was restricted to BCL2, we examined the effect of rhBCL2A1, an
anti-apoptotic BCL2 family member [11–13]. Mice were pre-
treated with rhBCL2A1 or rhBim on the day prior to I/R. Hind
limb ischemia was induced by aorta cross clamping for 90 minutes,
and plasma CK levels were measured 3 hours after reperfusion. As
shown in Figure 2A, the CK level was significantly less in the
rhBCL2A1-pretreated mice compared with the rhBim-pretreated
mice. These results demonstrate that another anti-apoptotic
protein of the BCL2 family has a similar cytoprotective function
when administered extracellularly.
In additional experiments, rats were pretreated with rhBCL2A1
in order to determine whether the protection noted in the mouse
following I/R injury was species-dependent. Plasma CK levels in
rats pretreated with rhBCL2A1 the day prior to tourniquet I/R of
hind limb were significantly less than CK levels in rats pretreated
with rhBim (Figure 2B).
BH4- and BH4-Like Peptides Protect Hind Limb Skeletal
Muscle from I/R Injury
The two anti-apoptotic members of the BCL2 family, rhBCL2
and rhBCL2A1, were protective against I/R injury when given
extracellularly, whereas the pro-apoptotic members, rhBim and
rhBax, were not. BCL2 contains an N-terminal domain,
designated BH4, which is present in several other anti-apoptotic
family members, but is not present in pro-apoptotic members such
as Bim or Bax. A BH4-like domain has been identified in the first
alpha-helix of BCL2A1 by molecular modeling [6]. Therefore, we
examined the role of the BH4 domain in the extracellular
cytoprotective function of BCL2.
When the BH4 domain of BCL2 was deleted (BCL2-delBH4),
pretreatment with this mutant BCL2 protein failed to protect
Extracellular BCL2 proteins
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following aorta cross-clamp and release were 12161 6 4578 after
pretreatment with rhBim vs. 16369 6 8109 with rhBCL2-delBH4;
p=0.66), consistent with a crucial role of BH4 domain in the
cytoprotective activity of extracellular rhBCL2. Peptides from the
BH4 domain of rhBCL2 (hBCL2-BH4) or the BH4-like domain of
rhBCL2A1 (hBCL2A1-BH4) were synthetized and tested in the I/
R experiments. Synthetic hBCL2-BH4 and hBCL2A1-BH4
peptides were both effective in reducing I/R, whereas a peptide
from the BH3 domain of Bak, a pro-apoptotic BCL2 family
member, was not (Figure 3).
Treatment with rhBCL2A1 Protein at the Time of or
Following Reperfusion Protects Skeletal Muscle against
I/R Injury
Mice were subjected to I/R of hind limb by tourniquet, and
tissue viability was measured at 24 hours after reperfusion using
MTT [9]. Viability of tissue was measured by the ability of
mitochondria to reduce MTT to a formazan salt that is insoluble
in water. The formazan crystals are soluble in isopropanol and are
extracted from tissue by incubating the tissue in isopropanol.
Thus, live tissue in this assay will have increased optical density
relative to dead tissue. Optical density of the tissue normalized to
tissue dry weight from mice treated with rhBCL2A1 protein given
subcutaneously at the time of reperfusion is shown in Figure 4A.
Clearly, the viability of tissue from mice treated with rhBCL2A1
protein was greater than that of mice treated with the control
protein rhBim. These experiments demonstrated that rhBCL2A1
protein was effective when administered at the time of reperfusion.
Notably, subcutaneous administration of rhBCL2A1 as late as
4 hours following reperfusion resulted in significantly greater tissue
viability at 24 hours after reperfusion compared with mice treated
with rhBim (Fig. 4B). Remarkably, treatment with as little as
100 ng per mouse of rhBCL2A1 (,5 mg/kg or ,4 picomoles) was
effective in reducing tissue injury (Fig. S1A) and treatment was
effective even when given up 72 hours prior to I/R (Fig. S1B).
These experiments demonstrate that rhBCL2A1 protein is
effective in attenuating I/R injury at cytokine-like doses given
prior to, at the time of, or following reperfusion.
Treatment with rhBCL2A1 Protein at the Time of
Reperfusion Reduces Myocardial Infarct Size at 24 Hours
C57BL/6 mice were subjected to 60 minutes of LAD coronary
artery occlusion with treatment at the end of ischemia by
subcutaneous injection of rhBCL2A1 or rhBim. Reperfusion was
then continued for 24 hours before evaluation of infarct size.
There was no difference in the volume at risk (VAR) relative to left
ventricle (LV) between the groups (Figure 5A). The infarct size
relative to the LV in rhBCL2A1-treated mice was significantly less
than in rhBim-treated mice. Mean infarct size, expressed as a
percentage of the VAR, was significantly less in the rhBCL2A1-
treated mice compared with rhBim-treated mice.
In additional experiments, C57BL/6 mice were subjected to
more severe ischemia by occluding the LAD coronary artery for
120 minutes with treatment at the end of ischemia at the time of
reperfusion by subcutaneous injection of rhBCL2A1 or rhBim.
Reperfusion was then continued for 24 hours before evaluation of
infarct size. There was no difference in VAAR relative to VLV
Figure 1. rhBCL2 protects hind limb skeletal muscle and cardiac muscle from I/R injury and apoptosis. (A) Creatine kinase (CK) levels in
plasma were determined in mice treated ip with rhBCL2 protein (1 mg/mouse) or rhUbiquitin (0.5 mg/mouse) or vehicle solution the day prior to the
hind limb I/R. Ischemia was produced by cross-clamping of the aorta for 90 min followed by 3 hrs of reperfusion. There were no differences in plasma
CK levels between the rhUbiquitin-treated and vehicle-treated mice, and results from these treatments were combined. Muscle injury following I/R
was significantly reduced by pretreatment with rhBCL2 (*p,0.05 rhBCL2 vs. control). (B) Mice were subjected to 60 minutes of LAD coronary artery
occlusion and 2 hours of reperfusion and then evaluated for infarct size. Volume of area at risk (VAAR), left ventricle volume (VLV), and infarct volume
(Vinfarct) were determined in mice pretreated the day prior to cardiac I/R with rhBCL2 (1 mg/mouse ip) or rhBim (1 mg/mouse ip). Treatment with
rhBCL2 significantly reduced Vinfarct compared to treatment with rhBim (*p,0.001). (C) The number of TUNEL-positive nuclei in skeletal muscle of
the rhBCL2-pretreated mice, expressed as a percent of the total number of nuclei, was reduced compared with control mice (*p,0.001). (D) The
number of TUNEL-positive nuclei in cardiomyocytes, expressed as a percent of the total number of nuclei, was reduced in rhBCL2-pretreated mice
compared with rhBim-pretreated mice (*p,0.001).
doi:10.1371/journal.pone.0009103.g001
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relative to VLV in rhBCL2A1-treated mice was significantly less
than in rhBim-treated mice. Infarct volume (Vinfarct), expressed as
a percentage of the VAAR, was significantly less in the rhBCL2A1-
treated mice compared with rhBim-treated mice.
TLR2-MyD88 Signaling Is Required for rhBCL2A1 to
Protect Hind Limb Skeletal Muscle against I/R Injury
Since BCL2 and BCL2A1 do not have significant primary
homology in the BH4 region, we reasoned that their effects in vivo
may involve a pattern recogniztion receptor. Since toll-like
receptors (TLRs), particularly TLR2 and TLR4, have been
demonstrated to recognize endogenous ligands, including DAMPs,
as well as microbial components [1,3,14], we examined TLR2 and
TLR4 signaling for their involvement in the protection afforded by
administration of rhBCL2 or rhBCL2A1.
C3H/HeJ mice with a mutation in TLR4 that prevents
signaling [15] were pretreated the day prior to tourniquet I/R
with rhBCL2 or rhBim. As shown in Figure 6A, plasma CK levels
were significantly lower in rhBCL2-treated mice than in mice
treated with rhBim.
TLR2-null (TLR2
2/2) mice (on a C57BL/6 background) were
subjected to tourniquet I/R, and treated with either rhBCL2A1 or
rhBim given subcutaneously at the time of reperfusion. Tissue
viability was measured at 24 hours after reperfusion using the
MTT assay [9]. These mice were compared with C57BL/6 mice
treated similarly with rhBCL2A1 or rhBim. Optical density of the
tissue normalized to tissue dry weight from mice treated at the
time of reperfusion is shown in Figure 6B. Clearly, the TLR2
2/2
mice were not protected by rhBCL2A1.
Figure 2. Pretreatment with rhBCL2A1 protects hind limb
skeletal muscle from I/R injury. (A) Plasma CK levels were
determined in mice pretreated with rhBCL2A1 protein (1 mg/mouse
ip) or rhBim (1 mg/mouse ip) the day prior to hind limb I/R by aorta
cross-clamping. Plasma CK levels were significantly decreased in the
rhBCL2A1-pretreated mice (*p,0.05). (B) Plasma CK levels were
measured in rats pretreated with rhBCL2A1 protein (10 mg/rat ip) or
rhBim (10 mg/rat ip) the day prior to hind limb I/R by tourniquet
induced for 90 minutes of ischemia, followed by 3 hours of reperfusion.
Plasma CK levels were significantly reduced in the rhBCL2A1-pretreated
rats (*p,0.05).
doi:10.1371/journal.pone.0009103.g002
Figure 3. Peptides from BH4 domains of hBCL2 and hBCL2A1
protect skeletal muscle From I/R injury. Mice were pretreated with
(A) synthetic BH4-BCL2 peptide (10 mg/mouse), (B) BH4-BCL2A1 peptide
(10 mg/mouse), (C) BH3-Bak peptide (10 mg/mouse), or control scram-
bled peptide (10 mg/mouse) given ip on the day prior to hind limb I/R
induced by tourniquet for 90 minutes of ischemia, followed by 3 hours
of reperfusion. Plasma CK levels were significantly less in mice
pretreated with hBCL2-BH4 or hBCL2A1-BH4 compared to mice
pretreated with a scrambled peptide (*p,0.05).
doi:10.1371/journal.pone.0009103.g003
Extracellular BCL2 proteins
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[16], we also examined MyD88-null (MyD88
2/2) mice.
MyD88
2/2 mice were subjected to tourniquet I/R treated with
rhBCL2A1 or rhBim at the time of reperfusion. Tissue viability
was measured at 24 hours after reperfusion using the MTT assay.
In concurrent experiments, C57BL/6 mice were treated similarly
with rhBCL2A1 or rhBim. Optical density of the tissue normalized
to tissue dry weight from mice treated at the time of reperfusion is
shown in Figure 6C. MyD88
2/2 mice were not protected by
treatment rhBCL2A1, indicating that the canonical TLR2-
MyD88 pathway was required.
Treatment with Exogenous rhBCL2 Protein Increases
Expression of Endogenous Mouse BCL2 Protein in
Skeletal and Cardiac Muscle Following I/R
Treatment with rhBCL2 or rhBCL2A1 reduced apoptosis of
skeletal and cardiac muscle following I/R, suggesting that the
protein might protect by inducing expression of an endogenous
anti-apoptotic protein(s). Consequently, we examined expression
of endogenous mouse (m)BCL2 protein in muscle cells following I/
R using an antibody specific for mouse BCL2. As shown in
Figure 7A there was minimal expression of mBCL2 protein after
I/R injury in skeletal muscle of control mice. However, tissue
following I/R from rhBCL2-treated mice showed a significant
increase in mBCL2 protein expression compared with control
mice (Figs. 7B and 7E). Likewise, mBCL2 protein expression in the
hearts of control mice exhibited minimal expression of mBCL2
protein following I/R (Figure 7C), whereas mBCL2 protein was
significantly increased in mice treated with rhBCL2 following I/R
injury (Figures 7D and 7E). Pretreatment with rhBCL2A1 also
increased expression of endogenous mBCL2 protein in skeletal
muscle cells following I/R (data not shown).
rhBCL2A1 Does Not Directly Activate TLR2 or Reduce
Apoptosis In Vitro
We attempted to replicate the in vivo activities of BCL2A1 using
in vitro models. rhBCL2A1 (up to 10 mg/ml) did not directly
activate TLR2 receptors as determined by IL-8 production in
HEK cells transfected with TLR2/6 (Fig. S2) or by nuclear factor-
kappa B (NF-kB)-dependent activation in THP1 macrophages
(Methods S1, Fig. S3). Also, the response of THP-1 macrophage
cells to several TLR2 ligands was unaffected by pretreatment with
rhBCL2A1 (Methods S1, Fig. S4).
We determined effect of rhBCL2A1 on the induction of
apoptosis in vitro in number of other cell types (e.g., endothelial,
fibroblasts, lymphocytes) challenged with a variety of pro-
apoptotic stimuli (e.g., Fas, H202) (unpublished observations).
Results in HEK TLR2/6 transfectants challenged with etoposide
Figure 4. Treatment with rhBCL2A1 at the time of or following
reperfusion protects hind limb skeletal muscle from I/R injury.
Mice were subjected to tourniquet ischemia for 90 minutes, and then
treated with subcutaneous rhBCL2A1 or rhBim (1 mg/mouse) at the
time of reperfusion (A) or 4 hours after the start of reperfusion (B).
Tissue viability was measured the following day by MTT assay (see
methods section). Tissue viability was significantly greater in the
rhBCL2A1-treated mice compared with the rhBim-treated mice
(*p,0.05).
doi:10.1371/journal.pone.0009103.g004
Figure 5. Treatment with rhBCL2A1 at the time of reperfusion
reduces myocardial infarct size after I/R. Mice were subjected to
LAD artery occlusion for 1 (A) or 2 (B) hours, and treated with
subcutaneous rhBCL2A1 (1 mg/mouse) or rhBim (1 mg/mouse) at the
time of reperfusion. Infarct size was determined after 24 hours of
reperfusion (see Methods). Treatment with rhBCL2A1 at the time of
reperfusion reduced infarct size at 24 hours of reperfusion (*p,0.05).
doi:10.1371/journal.pone.0009103.g005
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are shown in Figures S5 and S6, respectively.
Discussion
The results of experiments described in this report demonstrate
a previously unreported extracellular cytoprotective function for
the intracellular anti-apoptotic proteins, BCL2 and BCL2A1.
Thus, BCL2 and BCL2A1 and BH4-domain peptides join a
growing list of intracellular DAMPs (reviewed in [2,3]).
The BCL2 family contains both pro- and anti-apoptotic
proteins and their intracellular actions regulating apoptosis have
been extensively investigated (reviewed in [4]). There are two sub-
families of pro-apoptotic proteins with one sub-family consisting of
multiple domain proteins (Bax, Bak, Bod) and the other sub-family
consisting of BH3 domain-only proteins (e.g., Bim, Bad, and
Bik)(reviewed in [17]). The anti-apoptotic members of the BCL2
family have multiple domains, and most, but not all, have a
primary structure designated as the BH4 domain (reviewed in
[17]). The secondary structure of BCL2L1 (Bcl-xL) [18] and a
chimeric BCL2L1/BCL2 protein [19] have been determined and
shown to contain multiple alpha-helices with the N-terminal
alpha-helix containing the BH4 domain. The BH4 domain has
been shown to be necessary for the anti-apoptotic function of
intracellular BCL2 [20]. Although the primary structure of
Figure 6. Protection of hind limb skeletal muscle from I/R
Injury requires TLR2-MyD88 but not TLR4 signaling. (A) C3H/HeJ
(TLR4 mutant) mice were pretreated with rhBCL2 (1 mg/mouse ip) or
rhBim (1 mg/mouse ip) on the day prior to I/R. Mice were subjected to
90 minutes of hind limb ischemia by tourniquet, followed by 3 hours of
reperfusion. CK levels in the plasma from mice were reduced by
pretreatment with rhBCL2 (*p,0.05). (B)(C) C57BL/6, TLR2
2/2 or
MyD88
2/2 mice were pretreated with rhBCL2A1 or rhBim given
subcutaneously (1 mg/mouse) at the time of reperfusion. Tissue viability
was assessed after 90 minutes of hind limb ischemia by tourniquet and
24 hours of reperfusion. Tissue viability in TLR-2
2/2 (B) and MyD88
2/2
(C) mice treated with rhBCL2A1 or rhBim was reduced compared to
C57BL/6 mice treated with rhBCL2A1 (*p,0.05).
doi:10.1371/journal.pone.0009103.g006
Figure 7. Expression of endogenous mouse BCL2 protein in
cardiomyocytes and hind limb skeletal muscle cells is
increased after I/R in mice treated with rhBCL2. Expression of
endogenous mouse (m) BCL2 protein in tissue subjected to I/R was
determined by staining with a mouse-specific anti-BCL2 antibody. (A, B)
Mice were pretreated ip with (A) rhUbiquitin (1 mg/mouse) or (B) rhBCL2
(1 mg/mouse) on the day prior to hind limb I/R by tourniquet induced
by 90 minutes of ischemia followed by 3 hours of reperfusion. (C, D)
Mice were pretreated with (C) rhBCL2 (1 mg/mouse) or (D) rhBim (1 mg/
mouse) on the day prior to cardiac I/R induced by 60 minutes of
ischemia and 2 hours of reperfusion. Expression of endogenous mBCL2
protein was increased in skeletal muscle and cardiomyocytes after I/R in
the rhBCL2-pretreated mice compared to mice pretreated with
rhUbiquitin or rhBim. The scale bar represents 100 mm. (E) Quantitative
morphometric analysis on the skeletal muscle and heart from rhBCL2-
pretreated mice, respectively. Skeletal muscle and heart from rhBCL2-
pretreated mice showed increased expression of endogenous mBCL2
protein compared with tissue from mice pretreated with control
proteins (*p,0.05).
doi:10.1371/journal.pone.0009103.g007
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modeling Zhang et al [6] showed that there is a structural homolog
of the BH4 domain in the first alpha-helix of BCL2A1. In contrast,
pro-apoptotic BCL2 family members such Bax or Bim do not have
either the primary or secondary structure of a BH4 or BH4-like
domain [21].
In experiments reported here, pretreatment with synthetic
peptides from the BH4 domain of BCL2 and the BH4-like domain
of BCL2A1 conferred protection, whereas deletion of the BH4
domain from BCL2 abrogated protection against I/R injury.
These results suggest that the secondary structure of the BH4 or
BH4-like domain was critical to the extracellular cytoprotective
activity. There are several reports showing that a construct of the
BH4 peptide from Bcl-Xl conjugated to the cell penetrating HIV-
TAT peptide sequence blocked apoptotic cell death in vitro [22–25]
and in vivo [25–27]. However, our studies are the first to show an
extracellular function in vivo for a BCL2-BH4 or BCL2A1-BH4
peptide without a protein transduction domain.
The predicted structural homology between the BH4 domain of
BCL2 and the first alpha-helix of BCL2A1 (i.e., BH4-like domain)
[6], suggested that the protective effect of BCL2, BCL2A1 and
their respective BH4 peptides may involve a pattern recognition
receptor. Since toll-like receptors have been shown to recognize a
broad spectrum of microbial products as well as DAMPs [2,3], we
investigated their involvement in the reduction of skeletal muscle
I/R injury provided by rhBCL2 or rhBCL2A1. The protection
observed against I/R injury in the C3H/HeJ mice indicated that
the protective effect of rhBCL2 was not dependent upon TLR4
signaling. In contrast, the failure of rhBCL2A1 to protect the
TLR2
2/2 or MyD88
2/2 mice demonstrates that TLR2 signaling
through a MyD88-dependent pathway is required for in the
reduction in injury. Of interest, TLR2 has been shown to be a
primary sensor of necrotic cells [28,29]. Although implicated in
pro-inflammatory responses after I/R (reviewed in [30]), TLR2
signaling has also been shown to be protective in some I/R models
[31–33]. In contrast to reports in other I/R models (e.g., [30]),
neither the TLR2
2/2 nor the MyD88
2/2 mice exhibited
increased hind limb skeletal muscle injury compared to controls.
This may reflect the severity of our model with a prolonged
ischemia time that produces an injury that is not dependent upon
leukocytes [7].
The skeletal muscle cell injury produced by extended I/R was
previously shown to have a prominent component of apoptosis as
measured by TUNEL staining, and active caspase-3 staining and
by reduction of injury by a broad-spectrum caspase inhibitor [7].
Mice treated with rhBCL2 or rhBCL2A1 protein exhibited
significantly less apoptosis in affected tissue following I/R.
Previous investigations have shown over-expression of BCL2 in
critical target cells reduces organ injury following I/R (e.g.,
[34–40]). Notably, mice treated with rhBCL2 or rhBCL2A1
showed increased endogenous mBCL2 protein expression in heart
or skeletal muscle following I/R. These results suggest that one
mechanism by which exogenously administered rhBCL2 or
rhBCL2A1 protects tissue against I/R-induced apoptosis is by
augmenting increased expression of endogenous mouse BCL2. Of
note, we have not been able to detect a direct effect of rhBCL2 or
rhBCL2A1 on apoptosis in vitro in HEK TLR2 transfectants
challenged with etoposide or in a myeloid cell line subjected to
growth factor deprivation (Figs. S5 and S6) or in a number of
other cell types (e.g., endothelial, fibroblasts, lymphocytes)
challenged with a variety of pro-apoptotic stimuli (e.g., Fas,
H202) (unpublished observations). Given the lack of a detectable
direct effect in vitro, the TLR2 dependence in vivo, and the efficacy
with picomole quantities of protein, it seems unlikely that the
potent anti-apoptotic effect observed in vivo reflects uptake of
protein and inhibition of apoptosis by the usual mechanisms
ascribed to BCL2. As discussed below, it is more likely that the
anti-apoptotic activity of extracellular BCL2 or BCL2A1 in vivo in
the setting of I/R involves a novel pathway, perhaps akin to
preconditioning induced by other DAMPs or by TLR ligands
[41].
The cellular and molecular pathway(s) from rhBCL2A1 or
rhBCL2 ) TLR2-MyD88 ) cytoprotection in vivo remains to be
elucidated. Although TLR2-MyD88 signaling is required in vivo,a t
concentrations relevant to the in vivo studies rhBCL2A1 does not
directly activate TLR2 in vitro. There are several potential
explanations for this discrepancy between the in vivo and in vitro
results. First, there may be an intermediate effector cell in vivo that
then elaborates an endogenous TLR2 ligand(s) in response to
stimulation by rhBCL2A1 or rhBCL2. Second, the BCL2A1-
triggered cytoprotective pathway may be present only in a subset
of TLR2-expressing cells. In this regard, inflammatory monocytes,
but not bone marrow-derived macrophages or dendritic cells, were
recently shown to produce type 1 interferon via TLR2-MyD88
signaling in response to viral but not bacterial ligands [42].
Notably, induction of type 1 interferon in inflammatory monocytes
required internalization of TLR2. Third, BCL2, BCL2A1, or
BH4-domain peptides may require a co-factor for activity in vivo.
For example, it has recently been shown that recombinant high
mobility box 1 protein (HMGB1), a prototypic alarmin or DAMP,
lacks significant activity in vitro when it is highly purified [43–45],
but acquires activity in vitro upon binding to some TLR ligands
[45] or cytokines [44]. (Interestingly, although first characterized
by its pro-inflammatory activities, preconditioning with low-doses
of HMGB1 confers protection in liver I/R injury [46].) Finally,
TLR2 heterodimerizes with TLR1 and TLR6, and TLR2
signaling is modulated by other non-TLR receptors such as
dectin-1 [47], asioloGM1 [48], and CXCR4 [49]. It is possible
that BCL2 or BCL2A1 protein engages a co-receptor and that co-
operative signaling by this receptor and TLR2 (engaged by
endogenous ligands generated with tissue injury) promotes
cytoprotection. Such a scenario has been proposed for the
cardioprotection observed following treatment with b-glucan
[50], a dectin-1 ligand.
In summary, we report that severe I/R injury to skeletal or
cardiac muscle was reduced by very low doses of exogenously
administered rhBCL2 protein or rhBCL2A1 protein or BH4
peptides. These results demonstrate a novel, cytokine-like function
for extracellular BCL2 and BCL2A1 proteins as cytoprotective
DAMPs. In this regard, in preliminary studies we have detected
BCL2 in supernatant medium of lysed cells (Fig. S7). More
importantly, soluble BCL2 protein has been detected in serum in a
variety of disorders [51–55] and cerebrospinal fluid in traumatic
brain injury [56,57]. Notably, in children following head trauma
increased levels of soluble BCL2 protein in spinal fluid correlated
with improved survival [57]. Since a BH4-domain containing
peptide is generated by caspase cleavage of BCL2, it is likely that
BH4-peptides are also released extracellularly [58]. We further
speculate that the BH4-containing proteins or peptides interact
with cells in target tissue or, perhaps more likely, with an
intermediate effector cell to prime for a cytoprotective response in
stressed tissue. The inability of rhBCL2A1 to protect the TLR2
2/2
or MyD88
2/2 mice against I/R injury of skeletal muscle indicates
a requisite role for TLR2-MyD88 signaling for cytoprotection
in vivo.
Finally, the protective effect of the extracellularly administered
BH4-domain proteins is not limited to I/R. In other studies, we
found that treatment with rhBCL2 or rhBCL2A1 reduced
Extracellular BCL2 proteins
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(manuscript in preparation). In preliminary studies, treatment with
a single dose of rhBCL2A1 also significantly attenuated cardio-
myocyte apoptosis, heart weight gain, and fibrosis in a heart failure
model (Methods S1; Figs. S8 and S9). Thus, extracellular
administration of BH4-containing proteins or peptides may offer
a new approach to therapy of human diseases associated with cell
death.
Supporting Information
Methods S1
Found at: doi:10.1371/journal.pone.0009103.s001 (0.04 MB
DOC)
Figure S1 Protection against I/R injury by rhBCL2A1 is dose-
dependent and persists for up to 72 hours. (A) Mice were subjected
to tourniquet ischemia for 90 minutes, and treated with
subcutaneous rhBCL2A1 (1 I ˆJg/mouse) at the time of reperfu-
sion. Tissue viability, measured the following day by MTT assay,
was increased by treatment with rhBCL2A1 in dose-dependent
manner (*p,0.01 vs. saline, **p,0.05 vs. saline). (B) Mice were
treated with subcutaneous rhBCL2A1 or rhBim (1 I ˆJg/mouse) at
72 hrs prior to 90 minutes of ischemia followed by 24 hours of
reperfusion. Tissue viability as measured by MTT assay was
significantly greater in the rhBCL2A1-treated mice compared with
the rhBim-treated mice (*p,0.05).
Found at: doi:10.1371/journal.pone.0009103.s002 (7.23 MB TIF)
Figure S2 rhBCL2A1 does not induce release of IL-8 from
TLR2/6-transfected HEK cells. Wild-type human embryonic
kidney (HEK) cells and HEK-293 cells stably transfected with
TLR2 and TLR6 (HEK TLR2/6) were obtained from InvivoGen
(San Diego, CA). The HEK cells were incubated with BCL2A1
protein (10 I ˆJg/ml) or with the TLR2/6 ligand FSL-1 (100 ng/
ml; InvivoGen) for six hours. Supernatant medium was sampled
for IL-8 determination by ELISA (eBioscience).
Found at: doi:10.1371/journal.pone.0009103.s003 (0.14 MB TIF)
Figure S3 rhBCL2A1 does not induce NF-kappa B activation in
THP-1 macrophage-like cells. CControl medium or medium
containing BCL2A1 protein (0.1, 0.5 or 1 I ˆJg/ml) or E. coli
lipopolysaccharide (LPS) (0.1, 1 or 10 ng/ml) was incubated with
THP1-Blue (TM) cells for 24 h. Samples were removed for
analysis of NF-kappa B production by secreted embryonic alkaline
phosphatase (SEAP) as described below in Methods. Gray bar,
control medium; open bars, BCL2A1 protein; black bars, LPS.
Results represent means A ˆ6 SD of 6 replicates.
Found at: doi:10.1371/journal.pone.0009103.s004 (0.21 MB TIF)
Figure S4 BCL2A1 does not alter NF-kappa B activation in
response to other TLR2 ligands. Control medium or BCL2A1
protein (100 ng/ml) was placed on THP1-Blue (TM) cells followed
by the addition of Pam3CSK4 (100 ng/ml), zymosan (25 I ˆJg/
ml), or FSL-1 (10 or 100 ng/ml). Samples were removed to
Quanti-Blue (TM) for measurement of SEAP production as
described below. Ordinate: Quanti-Blue (TM), net absorbance.
Open bars, control medium; black bars, BCL2A1 protein.
Found at: doi:10.1371/journal.pone.0009103.s005 (0.15 MB TIF)
Figure S5 BCL2A1 protein or TAT-BCL2L1-BH4 peptide does
not protect HEK cells from apoptosis. Wild-type (WT) or TLR2/
6-transfected HEK-293 cells were treated overnight in complete
medium alone or medium with (A) BCL2A1 protein (300 ng/ml)
or (B) TAT-BCL2L1-BH4 (Bcl2-Xl) peptide (1 I ˆJg/ml). TAT-
BCL2L1 consists of the BH4 domain of BCL2L1 (aa 4–23) linked
to a protein transduction domain peptide from HIV-TAT (aa 48–
57) (EMD Chemicals, Inc., USA). After removal of medium, cells
were then treated with etoposide (20 I ˆJM) in complete medium
for 23 hrs and assessed for viability with Alamar Blue. Open bars,
control medium; black bars, (A) BCL2A1 or (B) TAT-BCL2L1-
BH4.
Found at: doi:10.1371/journal.pone.0009103.s006 (0.19 MB TIF)
Figure S6 BCL2A1 does not prevent apoptosis induced by
growth factor withdrawal. 332D myeloid cells are dependent upon
IL-3. 32D cell were grown overnight in complete medium
containing IL-3 with or without BCL2A1 (30 I ˆJg/ml). The cells
were then aliquoted to fresh medium with or without IL-3. Cells
pretreated with BCL2A1 (A1) overnight were further divided to
different concentrations of BCL2A1 (0 to 30 I ˆJg/ml). After a
24 hr incubation viability was determined by Alamar Blue assay
(Invitrogen).
Found at: doi:10.1371/journal.pone.0009103.s007 (0.21 MB TIF)
Figure S7 Necrotic cells release BCL2. Jurkat cells, a human T-
cell line, were lysed in one ml of complete lysis buffer or were
suspended in one ml of PBS containing protease inhibitor cocktail
(Sigma) and subjected to three cycles of freeze-thaw. Cell debris
was removed by centrifugation at 600 g for 10 min and then
12,000 g for 20 min. Protein concentrations were determined and
detergents and EDTA were then added to the freeze-thaw sample
to mimic the lysed sample. hBCL2 protein in supernatants was
measured by ELISA (R and D Systems), according to the
manufacturer’s directions.
Found at: doi:10.1371/journal.pone.0009103.s008 (0.17 MB TIF)
Figure S8 rhBCL2A1 reduces cardiac hypertrophy and apopto-
sis induced by aorta-banding. (A) Bar graph shows the effect of
rhBCL2A1 treatment on heart weight/body weight ratio at 3
weeks after aorta-banding procedure. At the time of aorta-banding
mice were injected subcutaneously with rhBCLA1 or rhBim
(1I ˆJg/mouse). (*p,0.05) (B) Bar graph showing the effect of
rhBCL2A1 on DNA strand breaks by TUNEL staining of heart at
3 weeks after aorta-banding procedure. At the time of aorta-
banding mice were injected subcutaneously with rhBCLA1 or
rhBim (1I ˆJg/mouse). (*p,0.05)
Found at: doi:10.1371/journal.pone.0009103.s009 (5.66 MB TIF)
Figure S9 hBCL2A1 reduces development of cardiac fibrosis
following aorta-banding. Histological sections of hearts were
stained with Sirius-red to highlight collagen. (A, B) show hearts
from rhBim-treated animal, (C, D) from rhBCL2A1-treated
animal. (A, C) show perivascular fibrosis, and (B, D) show
myocardial fibrosis. (original magnification: 640). (E, F) show
quantification by morphometry of the Sirius-red staining area. (E)
illustrates perivascular fibrosis index as measured by perivascular
collagen normalized to the vascular luminal area. (F) illustrates
myocardial interstitial fibrosis determined as percent of collagen
area to myocardial area in microscopic field. (*p,0.05)
Found at: doi:10.1371/journal.pone.0009103.s010 (5.43 MB TIF)
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